5.1 Immunosuppression After Liver Transplant

Immunosuppression After Liver Transplantation

Summary of Lecture by Prof. Sanjaya Satapathy, MD, FAASLD

1. Main Clinical Topics Discussed

• Principles and framework of post-liver transplant immunosuppression
• Three-phase model of immunosuppression management
• Major drug classes, their mechanisms, and toxicity profiles
• The "net state of immunosuppression" concept
• Drug interactions involving calcineurin inhibitors (CNIs)
• Differential diagnosis of post-transplant liver dysfunction
• Board examination strategies for transplant hepatology

2. Key Learning Points, Guidelines, and Recommendations

The Three-Phase Model

• Phase 1 – Induction (Inpatient/Early Post-Transplant):

- Highest acute rejection risk

- High-dose corticosteroids ± antibody therapy based on center protocol and patient risk profile

• Phase 2 – Maintenance (Months to Years):

- CNI-based backbone (predominantly tacrolimus)

- Adjunct agents added based on renal function, rejection history, and malignancy risk

- Most board-relevant clinical decisions occur in this phase

• Phase 3 – Minimization (Long-Term):

- Rejection risk declines; cumulative toxicity becomes the dominant concern

- Focus shifts to nephrotoxicity reduction, metabolic management, infection prevention, and malignancy surveillance

Four Major Drug Buckets

• Calcineurin Inhibitors (CNIs): Tacrolimus (first-line, most widely used worldwide); cyclosporine (less common, still board-relevant)
• Adjunct Agents: Mycophenolate mofetil (MMF) primary; azathioprine less frequently used
• mTOR Inhibitors: Sirolimus and everolimus — used for renal sparing or malignancy risk reduction
• Corticosteroids: Near-universal early use; long-term use varies by center and patient risk

The Net State of Immunosuppression

• Not defined solely by drug levels; determined by the sum of all immunological risk factors, including:

- Induction intensity

- Current drug doses and trough levels

- Time from transplant

- Recent rejection treatment (pulse steroids, anti-thymocyte globulin)

- CMV serostatus

- Active infection, leukopenia, malnutrition, renal failure

• Clinical implication: The same tacrolimus trough level may represent over-immunosuppression in one patient and under-immunosuppression in another

3. Key Drug Toxicity Profiles

4. Critical Drug Interactions (CYP3A4 Pathway)

• Drugs that INCREASE CNI levels (inhibitors):

- Azole antifungals (fluconazole, voriconazole)

- Macrolide antibiotics (clarithromycin, erythromycin)

- Protease inhibitors

- Grapefruit juice

• Drugs that DECREASE CNI levels (inducers):

- Rifampin (potent inducer)

- Phenytoin, carbamazepine

- St. John's Wort

> Board Pearl: Sudden unexplained rise in tacrolimus → suspect inhibitor co-administration. Sudden rejection after new medication → suspect CYP3A4 inducer causing subtherapeutic levels.

##